RAPT Therapeutics Announces License Agreement and Private Placement

RAPT Therapeutics, Inc. recently disclosed key developments in an 8-K filing with the Securities and Exchange Commission. The document, dated December 23, 2024, outlined significant agreements and initiatives undertaken by the company. In the announcement, RAPT Therapeutics revealed its entry into a license agreement with Shanghai Jemincare Pharmaceutical Co., Ltd. Additionally, the company disclosed a […]

Leave a Reply

Your email address will not be published.

Previous post Track Group, Inc. Announces Financial Results for Year Ended September 30, 2024
Next post Jamf Holding Corp. (NASDAQ:JAMF) Receives Consensus Recommendation of “N/A” from Brokerages